Page 322 - medicina-integrativa_compress

318 PARTE II, SECCIÓN 4 ENFERMEDADES CARDIOVASCULARES

64. Jepson RG, Kleijnen J, Leng GC: Garlic for peripheral arterial 87. Strano A, Pinto A, Galati D: Double-blind controlled study of the
occlusive disease. Cochrane Database Syst Rev Issue 2, 1997. efficacy and pharmacological properties of heparan sulfate in
65. Kiesewetter H, Jung F, Jung EM, et al: Effects of garlic coated tablets patients with occlusive arterial disease of the lower limbs. Drugs Exp
in peripheral arterial occlusive disease. Clin Invest 71:213-215, 2001. Clin Res 16:543-550, 1990.
66. Czerny B, Samochoweiec J: [Klinische Untersuchungen 88. Laurora G, Ambrosoli L, Cesarone MR, et al: Treatment of
mit einem Knoblauc Lezithin-Praparat.] Arztezeitschr intermittent claudication with defibrotide or mesoglycan: A double-
Naturheilverf 37:126-129, 1996. blind study. Panminerva Med 36:83-86, 1994.
67. Boger RH, Bode-Boger SM, Thiele W, et al: Restoring vascular 89. Raso AM, Maggio D, Trogolo M, et al: Effectiveness of mesoglycan
nitric oxide formation by L-arginine improves the symptoms of therapy in patients with ischemia of the lower limbs: Preliminary
intermittent claudication in patients with peripheral arterial results of a new therapeutic protocol. Minerva Cardioangiol
occlusive disease. J Am Coll Cardiol 32:1336-1344, 1998. 45:383-392, 1997.
68. Maxwell AJ, Anderson BE, Cooke JP: Nutritional therapy for 90. Zannetti S, L’Italien GJ, Cambria RP: Functional outcome after
peripheral arterial disease: A double-blind, placebo-controlled, surgical treatment for intermittent claudication. J Vasc Surg 24:65,
randomized trial of HeartBar. Vasc Med 5:11-19, 2000. 1996.
69. Miller ER III, Pastor-Barriuso R, Dalal D, et al: Meta-analysis: 91. Accessed from ?UpToDate 2006 at www.uptodate.com on January
High-dosage vitamin E supplementation may increase all-cause 12, 2006.
mortality. Ann Intern Med 142:37-46, 2005. 92. Warber SL, Zick SM: Peripheral vascular disease. In Rakel D (ed):
70. Violi F, Loffredo L, Marcoccia A: Antioxidants in peripheral arterial Integrative Medicine. Philadelphia, WB Saunders, 2003,
disease. Curr Drug Targets Cardiovasc Haematol Disord 4:289-294, pp 190-193.
2004. 93. Ernst E: Chelation therapy for peripheral arterial occlusive disease:
71. Klipstein-Grobusch K, den Breeijen, Grobbee DE, et al: Dietary A systematic review. Circulation 96:1031-1033, 1997.
antioxidants and peripheral arterial disease: The Rotterdam Study. 94. Sloth-Nielsen J, Guldager B, Mouitzen C, et al: Arteriographic
Am J Epidemiol 154:145-149, 2001. findings in EDTA chelation therapy on peripheral arteriosclerosis.
72. Kleijnen J, Mackerras D: Vitamin E for intermittent claudication. Am J Surg 162:122-125, 1991.
Cochrane Database Syst Rev Issue 4, 2005. 95. Van Rij AM, Solomon C, Packer SGK, et al: Chelation therapy for
73. Tornwall ME, Virtamo J, Haukka JK, et al: The effect of alpha- intermittent claudication. Circulation 90:1194-1199, 1994.
tocopherol and beta-carotene supplementation on symptoms and 96. Guldager B, Jelnes R, Jorgensen SJ, et al: EDTA treatment of
progression of intermittent claudication in a controlled trial. intermittent claudication: A double-blind, placebo-controlled study.
Atherosclerosis 147:193-197, 1999. J Intern Med 231:261-267, 1992.
74. Ferrari R, Merli E, et al: Therapeutic effects of L-carnitine and 97. Villarruz MV, Dans A, Tan F: Chelation therapy for atherosclerotic
propionyl-L-carnitine on cardiovascular diseases: A review. Ann NY cardiovascular disease. Cochrane Database Syst Rev (4) 2005.
Acad Sci 1033:79-91, 2004. 98. Kniazeva TA, Titova GA, Gusarov II: [Rationale for treating patients
75. Arsenian MA: Carnitine and its derivatives in cardiovascular disease. with hypertension and atherosclerosis of the lower extremities with
Prog Cardiovasc Dis 40:265-286, 1997. iodine-bromine baths containing molecular iodine.] [Article in
76. Pepine CJ: The therapeutic potential of carnitine in cardiovascular Russian] Vopr Kurortol Fizioter Lech Fiz Kult 1:16-19, 2005.
disorders. Clin Ther 13:2-21, 1991. 99. Brockow T, Hausner T, Dillner A, et al: Clinical evidence of
77. Deckert J: Propionyl-L-carnitine for intermittent claudication. J Fam subcutaneous CO 2 insufflations: A systematic review. J Altern Comp
Pract 44:533-534, 1997. Med 6:391-403, 2000.
78. Sabba C, Berardi E, Antonica G, et al: Comparison between the 100. Toriyama T, Kumada Y, Matsubara T, et al: Effect of artificial
effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in carbon dioxide foot bathing on critical limb ischemia (Fontaine IV)
chronic peripheral arterial disease: A haemodynamic double blind in peripheral arterial disease patients. Int Angiol 21:367-373, 2002.
echo-Doppler study. Eur Heart J 15:1348-1352, 1994. 101. Hartmann BR, Bassenge E, Pittler M: Effect of carbon dioxide-
79. Brevetti G, Diehm C, Lambert D: European multicenter study on enriched water and fresh water on the cutaneous microcirculation
propionyl-L-carnitine in intermittent claudication. J Am Coll and oxygen tension in the skin of the foot. Angiology 48:337-343,
Cardiol 34:1618-1624, 1999. 1997.
80. Brevetti G, Perna S, Sabba C, et al: Propionyl-L-carnitine in 102. Savin E, Bailliart O, Bonnin P, et al: Vasomotor effects of
intermittent claudication: Double-blind, placebo-controlled, transcutaneous CO 2 in stage II peripheral occlusive arterial
dose titration, multicenter study. J Am Coll Cardiol 26:1411-1416, disease. Angiology 46:785-791, 1995.
1995. 103. Hartmann BR, Bassenge E, Hartmann M: Effects of serial percutaneous
81. Brevetti G, Perna S, Sabba C, et al: Superiority of L-propionylcarnitine application of carbon dioxide in intermittent claudication: results of a
versus L-carnitine in improving walking capacity in patients with controlled trial. Angiology 48:957-963, 1997.
peripheral vascular disease: An acute, intravenous, double-blind, 104. Eyb R, Kelarides T: Die Akupunctur als Zusatzbehandlung bei
cross-over study. Eur Heart J 13:251-255, 1992. arteriellan Verschlusskrankeiten. Dtsch Z Akupunkt 2:42-46, 1988.
82. Hiatt WR, Regensteiner JG, Creager MA, et al: Propionyl-L-carnitine 105. Rosted P: Treatment of skin diseases with acupuncture: A review.
improves exercise performance and functional status in patients with J Dermatol Treat 6:241-242, 1995.
claudication. Am J Med 110:616-622, 2001. 106. Van Royen N, Piek J: Therapeutic manipulation of the collateral
83. O’Hara J, Jolly PN, Nicol CG: The therapeutic efficacy of inositol circulation: Future directions. Coron Artery Dis 15:399-403, 2004
nicotinate (Hexopal) in intermittent claudication: A controlled trial. 107. Van Royen N, Schirmer SH, Atasever B, et al: START Trial: A pilot
Br J Clin Pract 42:377-383, 1988. study on stimulation of arteriogenesis using subcutaneous
84. Head A: Treatment of intermittent claudication with inositol application of granulocyte-macrophage colony-stimulating factor
nicotinate. Practitioner 230:49-54, 1986. as a new treatment for peripheral vascular disease. Circulation
85. Inositol hexaniacinate. Altern Med Rev 3:222-223, 1998. 112:1040-1046, 2005.
86. Nenci GG, Gresele P, Ferrari G, et al: Treatment of intermittent 108. De Berrazueta JR, Sampedro I, Garcia-Unzueta MT, et al: Effect of
claudication with mesoglycan: A placebo-controlled, double-blind transdermal nitroglycerin on inflammatory mediators in patients with
study. Thromb Haemost 86:1181-1187, 2001. peripheral atherosclerotic vascular disease. Am Heart J 146:E14, 2003.